Evidence map›Paper›PMID 40182028›Full record

ArticleFrontiers in oncology2025

AI-enhanced cancer radiotherapy quality assessment: utilizing daily linac performance, radiomics, dosimetrics, and planning complexity.

Jia Deng, Yaolin Zhao, Dengdian Huang, Qingju Zhang, Ye Hong, Xiangyang Wu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jia DengSchool of Nuclear Science and Technology, Xi'an Jiaotong University, Xi'an, Shanxi, China.
Yaolin ZhaoSchool of Nuclear Science and Technology, Xi'an Jiaotong University, Xi'an, Shanxi, China.
Dengdian HuangBasic Technology Department, Science and Technology on Electromechanical Dynamic Control Laboratory, Xi'an, Shaanxi, China.
Qingju ZhangRadiation Oncology Department, Shaanxi Provincial Cancer Hospital, Xi'an, China.
Ye HongRadiation Oncology Department, Shaanxi Provincial Cancer Hospital, Xi'an, China.
Xiangyang WuRadiation Oncology Department, Shaanxi Provincial Cancer Hospital, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to develop and validate an Informer- Convolutional Neural Network (CNN) model to predict the gamma passing rate (GPR) for patient-specific quality assurance in volumetric modulated arc therapy (VMAT), enhancing treatment safety and efficacy by integrating multiple data sources. Methods: Analyzing 465 VMAT treatment plans covering head & neck, chest, and abdomen, the study extracted data from 31 complexity indicators, 123 radiomics features, and 123 dosimetrics indices, along with daily linac performance data including 141 key performance indicators. A hybrid Informer-CNN architecture was used to handle both temporal and non-temporal data for predicting GPR. Results: The Informer-CNN model demonstrated superior predictive performance over traditional models like Convolutional Neural Networks (CNN), Long Short-Term Memory(LSTM), and Informer. Specifically, in the validation set, the model achieved a mean absolute error (MAE) of 0.0273 and a root mean square error (RMSE) of 0.0360 using the 3%/3mm criterion. In the test set, the MAE was 0.0327 and the RMSE was 0.0468. The model also showed high classification performance with AUC scores of 0.97 and 0.95 in test and validation sets, respectively. Conclusion: The developed Informer-CNN model significantly enhances the prediction accuracy and classification of gamma passing rates in VMAT treatment plans. It facilitates early integration of daily accelerator performance data, improving the assessment and verification of treatment plans for better patient-specific quality assurance.

Indexed as

deep learninggamma passing ratepatient-specific quality assuranceprediction modelradiotherapy

Identifiers

PMID40182028
PMCPMC11966416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.